Dublin, Dec. 20, 2018 (GLOBE NEWSWIRE) -- The "Global Hemorrhagic Stroke Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The haemorrhagic stroke treatment market will register a CAGR of almost 4% by 2023.

The improved diagnostic modalities for haemorrhagic stroke recovery to help market grow. For the appropriate management of haemorrhagic stroke, an adequate understanding of parenchymal haemorrhage is crucial. Since intracerebral haemorrhage is an acute clinical manifestation of the underlying cerebral small vessel diseases (cSVDs), it is essential to use improved diagnostic modalities such as MRI markers to monitor the risk stratification.

Market Overview

Rising incidence in aging population

Increasing age is a major risk for several conditions, including intracerebral haemorrhages. This increases the demand for drugs thereby pushing growth in the haemorrhagic stroke treatment market.

High generic influx

The patent expiry of most of the products has paved the way for the entry of generics into the market. The excessive use of generic medicine can impede the demand for branded drugs, thereby affecting the market.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Baxter and Novartis, the competitive environment is quite intense. Factors such as the improved diagnostic modalities for haemorrhagic stroke recovery and the rising incidence in aging population, will provide considerable growth opportunities to haemorrhagic stroke treatment manufactures. Baxter, Novartis, Sanofi, and Pfizer are some of the major companies covered in this report.

With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Antihypertensives
  
• Anticoagulants
• Diuretics
• Anticonvulsants and others
• Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

PART 10: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Key leading countries
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

PART 15: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Baxter
• Novartis
• Pfizer
• Sanofi
  

For more information about this report visit https://www.researchandmarkets.com/research/ttgdgr/global?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiology , Neurology